Value of clinical psychologist's role in minimizing psychological distress in hepatitis C treatment

Not Applicable

• Conditions: hepatitis C; Psychiatric conditions; Infection - Other infectious diseases

• Registration Number: ACTRN12608000377336
• Lead Sponsor: J Arachchi

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2008-08-01
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 48

Inclusion Criteria

Age 18-70
Presence of Hepatitis C (on polymerase chain reaction) and eligible for pegylated interferon and ribavirn therapy
able to understand study protocol and consent

Exclusion Criteria

Current active psychiactric condition dignosed by a medical practitioner.
Pateints who are in regular care with a psychiatrist or a psychologist.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
reducation in psychological distress measured by K10( The Kessler Psychological Distress Scale) score (by 5 points)[At 12 weeks after the 1st dose of Interferon and ribavirin]

Secondary Outcome Measures

Name	Time	Method
reduction in psychaitric conditions diagnosed clinically by a psychaitrist.[At completion of interferon therapy which is 24 weeks for genotype 2,3 and 48 weeks for genotype 1];Virological response at the end of therapy by Polymerase chain reaction (PCR)[Week 24 for genotype 2 or 3 and week 48 for genotype 1];use of psychotrophic drugs[during the interferon therapy (week 24 for genotype 2,3 and week 48 for genotype 1)]